liposinol logo
spacer

Liposinol™ is clinically proven
spacer

Main page

What is Liposinol™?

How Liposinol™ works?

Liposinol™ is clinically proven

Why choose Liposinol™?

Is Liposinol™ for you?

More about Liposinol™





< back

2001

Fat Binding Capacity of Liposinol™ Patented Fibre Complex


The TNO-report is based on a gastro-intestinal model simulating very closely the dynamic processes in the gastro-intestinal tract such as the pH curves and concentrations of (pro-) enzymes in the stomach and small intestine, concentration of bile salts in the different parts of the gut, and the kinetics of passage of chime through the stomach and intestine1. This gastro-intestinal model is scientifically validated to correlate to the human GI functions. The results have been accepted by the USPDA & several other authorities.

Specific absorption systems have been developed for this model to study the absorption of fat digestion products and fat-soluble nutrients such as fat-soluble vitamins.

The aim of this study was to determine the fat binding capacity of the Liposinol™ patented fibre complex during passage through a dynamic, computer-controlled model of the stomach and small intestine.

iconTest products and diet:
spacer The mixture of Liposinol™ patented fibre complex and standardised meal was fed quantitatively to the model.
iconSampling and analysis:
 
The digestion and absorption of fat was tested for 4 hours in the model. Samples were taken in duplicate and stored at -20°C for analysis. The fatty acids in each fraction were analysed by gas chromatography after transesterification, the sum of the analysed fatty acids is expressed as total fatty acids (TFA).
iconResults:
spacer The experiments showed that the Liposinol™ patented fibre complex prevented the absorption of 2.7 grams of fatty acids during the four hours of experiment in the gastro-intestinal model.
Furthermore it was proven that the fat binding to the patented fibre complex of Liposinol™ is not selective for specific fatty acids, as the percentage bound to Liposinol™ was similar for each individual fatty acid (72 ± 7%).

liposinol, it's clinically proven

  
   Figure 1: Percentage of dietary fat absorption reduction
   by patented fibre complex.
iconConclusion:
spacerPatented fibre complex of Liposinol™ is able to bind to fat and thus prevent the absorption in the gastro¬intestinal tract. Since the described model simulates very closely the dynamic digestive processes, it can be expected that the product will reach similar results in vivo as shown in the in vitro experiments.
1 Minekus, M., Development and validation of a dynamic model of the gastrointestinal tract. PhD Thesis, University of Utrecht; Elinkwyk b.v., Utrecht, NL, (1998).